Novartis venture group turns attention to Malaysia

Novartis Venture Funds, which has been an active player in backing startups around the world, is planning to pick up the pace in Malaysia. Malaysian newspapers report that the fund, which has $700 million in investments under management, has signed a memo of understanding with government officials to help finance biopharma startups in the country. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.